Live Breaking News & Updates on Parkinson Disease Program

Stay updated with breaking news from Parkinson disease program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bethesda's Gain Therapeutics Presents New GBA1 Parkinson's Disease Program Pre-clinical Data · BioBuzz


Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model
Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase
Compounds decrease both phosphorylated and aggregated α
-synuclein levels in vitro and in vivo
BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pre-clinical data from its GBA1 Parkinson’s disease program. The findings were highlighted in a presentation at the XXVI International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, a research conference dedicated to Parkinson’s disease and other disorders affecting muscle tone and motor control, being held virtually May 1-4, 2021. ....

Ricardo Feldman , Madeline Joanis , Erici Richman , European Union Horizon , Gain Therapeutics Inc , International Association Of Parkinsonism , Silverstein Foundation For Parkinson , Lifesci Communications , University Of Maryland School Medicine , Michaelj Fox Foundation , Preclinical Development Of Brain , World Congress , Michaelj Fox Foundation For Parkinson Research , Parkinson Disease Program , Gain Therapeutics Presents New , Disease Program Pre Clinical , Gain Therapeutics , Related Disorders , Structurally Targeted Allosteric Regulators , Manolo Bellotto , General Manager , Site Directed Enzyme Enhancement Therapy , Associate Professor , Maryland School , Chief Executive Officer , Silverstein Foundation ,